Table 2 Universal influenza vaccine candidates in preclinical and clinical trials
From: Influenza vaccine: a review on current scenario and future prospects
Vaccine candidate | Vaccine type | Manufacturer | Clinical phase |
|---|---|---|---|
Chimeric HA proteins | Hemagglutinin based | Glaxo-SmithKline | Phase 1 |
(COBRA) Computationally optimized broadly reactive antigens | Computationally optimized antigens | Sanofi-Pasteur | Preclinical |
NP, M1 and HA peptides (Multimeric-001) | Recombinant proteins | BiondVax Pharmaceuticals Ltd. | Phase 3 |